Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2024 Apr;20(4):203-215.
doi: 10.1038/s41584-024-01084-x. Epub 2024 Feb 21.

The therapeutic potential of immunoengineering for systemic autoimmunity

Affiliations
Review

The therapeutic potential of immunoengineering for systemic autoimmunity

David A McBride et al. Nat Rev Rheumatol. 2024 Apr.

Abstract

Disease-modifying drugs have transformed the treatment options for many systemic autoimmune diseases. However, an evolving understanding of disease mechanisms, which might vary between individuals, is paving the way for the development of novel agents that operate in a patient-tailored manner through immunophenotypic regulation of disease-relevant cells and the microenvironment of affected tissue domains. Immunoengineering is a field that is focused on the application of engineering principles to the modulation of the immune system, and it could enable future personalized and immunoregulatory therapies for rheumatic diseases. An important aspect of immunoengineering is the harnessing of material chemistries to design technologies that span immunologically relevant length scales, to enhance or suppress immune responses by re-balancing effector and regulatory mechanisms in innate or adaptive immunity and rescue abnormalities underlying pathogenic inflammation. These materials are endowed with physicochemical properties that enable features such as localization in immune cells and organs, sustained delivery of immunoregulatory agents, and mimicry of key functions of lymphoid tissue. Immunoengineering applications already exist for disease management, and there is potential for this new discipline to improve disease modification in rheumatology.

PubMed Disclaimer

Similar articles

Cited by

References

    1. McInnes, I. B. & Gravallese, E. M. Immune-mediated inflammatory disease therapeutics: past, present and future. Nat. Rev. Immunol. 21, 680–686 (2021). - PubMed - PMC - DOI
    1. Fraenkel, L. et al. 2021 American College of Rheumatology Guideline for the treatment of rheumatoid arthritis. Arthritis Rheumatol. 73, 1108–1123 (2021). - PubMed - DOI
    1. Denis, A., Sztejkowski, C., Arnaud, L., Becker, G. & Felten, R. The 2023 pipeline of disease-modifying antirheumatic drugs (DMARDs) in clinical development for spondyloarthritis (including psoriatic arthritis): a systematic review of trials. RMD Open. 9, e003279 (2023). - PubMed - PMC - DOI
    1. Tuttle, J. et al. A phase 2 trial of peresolimab for adults with rheumatoid arthritis. N. Engl. J. Med. 388, 1853–1862 (2023). - PubMed - DOI
    1. Gravallese, E. M. & Thomas, R. Reinforcing the checkpoint in rheumatoid arthritis. N. Engl. J. Med. 388, 1905–1907 (2023). - PubMed - DOI

LinkOut - more resources